Press Release Archive 

 


2008-06-04
ViroGates Fully Subscribes New Financing Round
ViroGates raises new capital from both current and new investors to continue and expand suPARnostic® commercialization.


2008-05-07
ViroGates Enters Into a Long-Term Research Collaboration with Hvidovre Hospital
ViroGates A/S has entered into a long-term research collaboration with the Hvidovre Hospital’s Clinical Research Centre.  
 

2008-1-7
ViroGates Introduces Life-Saver
ViroGates has signed two exclusive distribution deals with carefully selected partners to market its suPARnostic® kit in Europe.


2007-11-22
ViroGates Appoints Professor Knut Borch-Johnsen
The company announced today the appointment of Professor Knut Borch-Johnsen as Scientific Advisor.


2007-9-18
ViroGates Changes Management and Board Structure
The biotech company today announced several changes in its management and board structure.


2007-7-26
ViroGates Closes New Financing Round with Successful Exit for DTU Innovation/SEED Capital
The biotech company announced today that it has closed a private financing round of DKK 14.5 million.


2007-1-18
ViroGates' HIV Monitoring Kit to be implemented in Denmark
ViroGates has entered into agreement with Hvidovre Hospital to supply the country’s largest HIV centre with its first-in-class HIV disease monitoring test.


2007-1-18
ViroGates Receives CE Certification
ViroGates has received CE Mark certification for its first-in-class HIV patient monitoring assay - the suPARnostic™ kit is the company’s first product to achieve the CE Mark certification.


2006-9-4
suPAR recognized as one of the most important Danish discoveries
The protein suPAR has been recognized by the Danish Patent and Trademark Office as one of the most important and life saving Danish inventions in life science.


2006-8-14
suPARnostic™ introduced at the XVI World AIDS Conference in Toronto 2006.


2006-6-22
ViroGates Oversubscribes 3 Times Its Latest Private Round
In its largest financing round to date, ViroGates raises new capital from both current and new investors.


2006-5-19
ViroGates nominated as most promising company in Medicon Valley
Foreign investors will get their first glimpse of ViroGates, as the small biotech company has been selected to present its business case to both UK and US investors in June.


2006-4-23
ViroGates Completes Development of First-In-Class HIV Prognostic Kit
After years of extensive research and development, ViroGates has completed production of the first batch of suPARnostic™ kits for the monitoring of HIV disease progression.